Abus Nasdaq

Arbutus Biopharma Corporation

ABUS | $2.61 -2.61% -0.77% |

(0.0% 1d) (7.4% 1m) (-13.9% 1y) (0.0% 2d) (-2.6% 3d) (-10.6% 7d) (-27.31% volume)
Earnings Calendar:
http://www.arbutusbio.com
Sec Filling | Patents | 80 employees

(US) Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

hepatitis

add to watch list email alert is off

Price chart

% (High / Open) change chart

Press-releases

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update
Published: 2022-06-25 (Crawled : 08:20) - globenewswire.com
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| Email alert Add to watchlist
ab-729 liver update international

Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
Published: 2022-06-08 (Crawled : 07:00) - globenewswire.com
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| 3.57% | O: 4.37% H: 7.22% C: 1.9%
liver international

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Published: 2022-06-06 (Crawled : 12:00) - globenewswire.com
VACC | $5.25 -9.79% 0.95% |

Manufacturing

| 25.3% | O: 7.88% H: 4.2% C: 4.2%
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| 1.36% | O: 6.02% H: 0.37% C: -6.23%
treatment hepatitis for virus trial

Arbutus to Participate in June Investor Conferences
Published: 2022-06-02 (Crawled : 12:00) - globenewswire.com
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| 2.76% | O: -3.15% H: 7.72% C: 7.32%

New Moderna CFO Abruptly Departs Over Investigation at Former Company
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
XRAY | News | $35.83 -2.45% 0.03% |

Health Technology

| 0.83% | O: 2.41% H: 0.0% C: 0.0%
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| 31.82% | O: -1.52% H: 13.85% C: 5.64%

Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Published: 2022-04-26 (Crawled : 18:00) - globenewswire.com
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| -0.76% | O: -2.28% H: 1.75% C: -3.5%
PHAT | $8.2 -9.29% -3.54% |

Health Technology

| -39.75% | O: -1.4% H: 0.78% C: -3.8%
EXEL | $20.94 -5.76% 0.1% |

Health Technology

| -8.32% | O: -0.44% H: 0.44% C: -2.15%
MYOV | $12.71 -2.53% 0.0% |

Health Technology

| 24.49% | O: -0.49% H: 2.85% C: -6.5%

Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
Published: 2022-04-21 (Crawled : 12:00) - globenewswire.com
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| 0.0% | O: -0.38% H: 0.0% C: 0.0%
report results

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments
Published: 2022-03-25 (Crawled : 12:00) - biospace.com/
VACC | $5.25 -9.79% 0.95% |

Manufacturing

| -0.19% | O: 0.95% H: 0.0% C: -15.07%
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| -13.58% | O: -0.66% H: 0.33% C: -3.67%
results

Alnylam Seeks "Fair Compensation" for Lipid Technology Used in mRNA COVID-19 Vaccines
Published: 2022-03-17 (Crawled : 16:00) - biospace.com/
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| -12.42% | O: -1.68% H: 4.95% C: 3.07%
covid-19 air technology covid vaccine

UPDATE: Alnylam Seeks "Fair Compensation" for Lipid Technology Used in mRNA COVID-19 Vaccines
Published: 2022-03-17 (Crawled : 17:00) - biospace.com/
ABUS | $2.61 -2.61% -0.77% |

Health Technology

| -12.42% | O: -1.68% H: 4.95% C: 3.07%
covid-19 air technology covid vaccine

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001447028-22-000035	4	2022-05-26	2022-05-25	Buy	A	41000	41000

Arbutus Biopharma Corporation

Price chart

% (High / Open) change chart

Press-releases

Last 15 days Sec forms

Your Today's Watch List

Last 48 Hours Insiders Buying